London:
UK-based pharmaceutical giant AstraZeneca mentioned Tuesday it will release additional information “within 48 hours” on US trials of its Covid-19 vaccine, soon after overall health officials raised issues about the initial information and facts disclosed.
The business pushed back against a statement from the US National Institute of Allergy and Infectious Diseases (NIAID) which mentioned that “outdated information” may possibly have been used to conclude that its vaccine was very powerful against Covid.
“We have reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis,” AstraZeneca mentioned in a statement.
“We intend to issue results of the primary analysis within 48 hours,” it added.
The US overall health agency’s evaluation comes soon after AstraZeneca mentioned on Monday that stage 3 US trials of the vaccine had shown it was 79 % powerful.
It follows controversy more than the vaccine’s rollout in Europe.
France, Germany and a quantity of other nations mentioned final week they would resume applying the jab soon after its introduction was suspended more than possible hyperlinks to blood clots amongst recipients.
Global overall health authorities as nicely as AstraZeneca insist the vaccine is secure.
EU officials have also hit out at AstraZeneca for delivering its UK provide contract in complete so far, when falling brief on supplies to the continent.
German Chancellor Angela Merkel on Tuesday backed the threat of a probable ban on exporting EU-created AstraZeneca vaccines out of the bloc.
()